Status:
WITHDRAWN
Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
NHS Greater Glasgow and Clyde
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
35-80 years
Phase:
PHASE4
Brief Summary
Some patients with chronic obstructive pulmonary disease (COPD) take nebulised treatments to ease the symptom of breathlessness, including the drug ipratropium. Nebulised bronchodilator drugs are take...
Detailed Description
Tiotropium and ipratropium bromide are both antimuscarinic bronchodilators, licensed for the treatment of COPD with a similar side-effect profile. Tiotropium administered by an inhaler device (Handiha...
Eligibility Criteria
Inclusion
- Stable Moderate to severe COPD (GOLD criteria)
- \> 20 pack year smoking history
- current treatment with nebulised ipratropium bromide
- no exacerbations within preceding 3 months
Exclusion
- current participation in other study
- \< 20 pack year smoking history
- Significant co-morbidity e.g. cardiac
- history of intolerance to lactose
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00335621
Start Date
June 1 2006
End Date
December 1 2007
Last Update
July 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Respiratory Medicine, Glasgow Royal Infirmary
Glasgow, United Kingdom, G4 0SF